RAH HD: Research-Action in Hematology From Hospitalization to Home

Sponsor
University Hospital, Caen (Other)
Overall Status
Completed
CT.gov ID
NCT06053918
Collaborator
(none)
10
1
22.8
0.4

Study Details

Study Description

Brief Summary

Objective :

To study and support the hospitalization and the return home of patients with the help of a psychological follow-up started in a hospital institution and which will continue in the patient's home, based on the concepts of transitionality and narrativity.

Material and method To do this, the subjects will benefit from psychological interviews where they will freely discuss what concerns them, whether it is illness, treatment, returning home, or any other personal subject.

They will be divided into two groups of 5 patients each, one of the groups will benefit from follow-up in an institution as contracted for several years between the Institute of Hematology and the psychologists of the UMDSP, another from the same follow-up but with the presence of the psychologist at the time of discharge extended to the patient's home after leaving the hospital for a period of 2 months.

To ensure a certain consistency in the evaluation criteria, these will be standardized in the form of questionnaires completed blindly by the patient, a caregiver and the investigator, at 3 key times of the research (entry, discharge from hospital, two months after this discharge)

Device tested:

The aim of this work is to test the benefits of a device based on transitionality, which can limit, thanks to the restoration of the symbolization process, the deleterious effects of each of the stages imposed by the disease, the care and the resumption of autonomy once the active phase of care has passed.

Narrativity is also at the heart of this transitional device. It makes it possible to evoke the present experience of the patient in connection with future projects and in the continuity of past, potentially traumatic events. It opens onto a dynamic temporal perspective where the trauma freezes.

The whole process promotes the subjective reappropriation of the experience and a psychic well-being.

Condition or Disease Intervention/Treatment Phase
  • Other: additional follow-up extension at home

Study Design

Study Type:
Observational
Actual Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Psychological Follow-up in a Protected Hematology Unit as a Transitional Device Between Hospitalization and Return Home
Actual Study Start Date :
May 7, 2019
Actual Primary Completion Date :
Mar 31, 2020
Actual Study Completion Date :
Mar 31, 2021

Arms and Interventions

Arm Intervention/Treatment
classic follow-up (Group A)

Group A will benefit from the classic follow-up, as it has been contractualized for several years now between the UMDSP and the hematology sector. Namely a psychological follow-up in the patient's room during the hospitalization time, once a week, more if the patient is going through a difficult passage that requires closer support. This follow-up is spread over an approximate period of 6 weeks maximum, depending on the length of hospitalization

Intervention group (Group B)

Group B will benefit from this same follow-up, to which will be added an interview when leaving the sector, and the extension of follow-up of the patient at home according to the same conditions: once a week, more if necessary, over a period of two months. This follow-up is spread over an approximate period of 15 weeks maximum, depending on the length of hospitalization.

Other: additional follow-up extension at home
additional interview when leaving the sector, and the extension of follow-up of the patient at home

Outcome Measures

Primary Outcome Measures

  1. Clinical evaluation of the psychological state, anxiety-depressive disorders [At hospital Month 0 and at home Month 2]

    anxiety-depressive disorders yes or no

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patient hospitalized Protected Hematology Unit

  • patient with haematologic cancer

  • patient requesting psychological assistance or accepting proposed psychological assistance

  • signed informed consent

Exclusion Criteria:
  • patient refusing to participate

  • patient not able to participate

Contacts and Locations

Locations

Site City State Country Postal Code
1 CAEN University Hospital Caen France

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT06053918
Other Study ID Numbers:
  • 18-199
First Posted:
Sep 26, 2023
Last Update Posted:
Sep 26, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 26, 2023